Palvella Therapeutics (PVLA) EPS (Basic) (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly EPS (Basic) of -$1.2 for Q1 2026, down 62.14% year-over-year from -$3.18 in Q1 2025, and down 6.1% quarter-over-quarter from -$1.14 in Q4 2025.
Palvella Therapeutics (PVLA) EPS (Basic) (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported EPS (Basic) for 14 consecutive years, with -$1.2 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) fell 62.14% year-over-year to -$1.2; the TTM figure through Mar 2026 stood at -$3.77 (down 81.51% YoY), while the FY2025 annual figure was -$3.71, up 52.59% from the prior year.
- EPS (Basic) eased to -$1.2 in Q1 2026 per PVLA's latest filing, from -$1.14 in the prior quarter.
- Across five years, EPS (Basic) topped out at $13.31 in Q4 2023 and bottomed at -$17.19 in Q1 2023.
- Historically, EPS (Basic) has averaged -$4.67 across 5 years, with a median of -$2.21 in 2024.
- Annual changes were most pronounced in 2023 — EPS (Basic) soared 200.18% — and 2024, when it slumped 335.57%.
- Palvella Therapeutics' EPS (Basic) stood at -$13.29 in 2022, then jumped by 200.18% to $13.31 in 2023, then tumbled by 111.37% to -$1.51 in 2024, then increased by 24.96% to -$1.14 in 2025, then fell by 6.1% to -$1.2 in 2026.
- Business Quant data shows PVLA's EPS (Basic) at -$1.2 in Q1 2026, -$1.14 in Q4 2025, and -$1.03 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 7.59 |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.06 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.16 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.18 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.23 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.06 |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | -1.52 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.52 |
| Mar 31, 2026 | -1.20 |
| Dec 31, 2025 | -1.14 |
| Sep 30, 2025 | -1.03 |
| Jun 30, 2025 | -0.86 |
| Mar 31, 2025 | -0.74 |
| Dec 31, 2024 | -1.51 |
| Sep 30, 2024 | -5.28 |
| Jun 30, 2024 | -3.36 |
| Mar 31, 2024 | -2.21 |
| Dec 31, 2023 | 13.31 |
| Sep 30, 2023 | -9.96 |
| Jun 30, 2023 | 1.43 |
| Mar 31, 2023 | -17.19 |
| Dec 31, 2022 | -13.29 |
| Sep 30, 2022 | -13.62 |
| Jun 30, 2022 | -13.95 |
| Mar 31, 2022 | -8.74 |
| Dec 31, 2021 | -14.50 |
| Sep 30, 2021 | -23.16 |